Xenon: director Hayden not standing for re-election; Pimstone to become Chair; exec comp approved

Xenon Pharmaceuticals Inc.

Michael Hayden will not stand for re-election at June 1, 2022 annual meeting; no disagreement with company.
Board appointed Dr. Pimstone as Chair of the Board, effective subject to his re-election as director.
2022 base salaries: Pimstone $525k, Mortimer $594k, Aulin $425k; retroactive to Jan 1, 2022.
2022 performance goals include XEN1101 Phase 3 start and MDD proof-of-concept trial initiation.
2021 non-equity incentive payments: Pimstone $450k, Mortimer $400k, Aulin $155k (in USD).

item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Simon N. Pimstone

Chair of the Board

XENE · Xenon Pharmaceuticals Inc.

Effective: 2022-06-01
Filed: March 10, 2022, 6:59 PM ET

appointed Dr. Pimstone, current Executive Chair of the Board, as Chair of the Board, effective upon and subject to his re-election as a director at the Annual Meeting.

Departed

Michael Hayden

Director

XENE · Xenon Pharmaceuticals Inc.

Effective: 2022-06-01
Filed: March 10, 2022, 6:59 PM ET

Michael Hayden, notified the Board that he would not stand for re-election as a director of the Board at the Annual Meeting.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Simon N. Pimstone was appointed as Chair of the Board at Xenon Pharmaceuticals Inc..

Action: appointed
Role: Chair of the Board

Exact text from the filing

appointed Dr. Pimstone, current Executive Chair of the Board, as Chair of the Board, effective upon and subject to his re-election as a director at the Annual Meeting.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Michael Hayden departed as Director at Xenon Pharmaceuticals Inc..

Action: not stand for re-election
Role: Director

Exact text from the filing

Michael Hayden, notified the Board that he would not stand for re-election as a director of the Board at the Annual Meeting.

View on SEC.gov

Xenon Pharmaceuticals Inc. filing history →

Source: SEC EDGAR

accession 0001564590-22-009639

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.